Protein may trigger treatment-resistant prostate cancer; Galectin-3 backed as cancer marker;

> Rutgers University investigators say they've identified a protein that may be the culprit behind treatment-resistant prostate cancer. Item   

> ApoCell, which specializes in biomarker detection and analysis, has been named one of Houston's fastest-growing private companies. Item

> A new case report published in Case Reports in Oncology backs up the use of Galectin-3 as a marker of cancer and inflammation. Item

> The companion biomarker sector should jump to $319 million by 2018, a new report concludes. Item

> Genalyte is working with the Barbara Davis Center for Childhood Diabetes at the University of Colorado School of Medicine to advance a biomarker panel for early diagnosis of Type 1 diabetes. Story

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.